Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

Head & Neck
M G FuryD G Pfister

Abstract

The purpose of this study was to evaluate the efficacy and tolerability of the addition of 2 monoclonal antibodies, bevacizumab and cetuximab, to 2 cycles of high-dose cisplatin administered concurrently with intensity-modulated radiation therapy (IMRT) for head and neck squamous cell carcinoma (HNSCC). Patients with newly diagnosed stage III/IVB (M0) HNSCC received cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2) weekly), bevacizumab (15 mg/kg, days 1 and 22), and cisplatin (50 mg/m(2) , days 1, 2, 22, and 23) concurrently with IMRT (70 Gy). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and safety and tolerability. Among 30 patients enrolled in this study, the primary tumor site was the oropharynx in 24 patients (p16 immunohistochemistry was positive in 17, negative in 1, and not done in 6 of the oropharyngeal tumors). Median age was 57 years (range, 38-77 years) and 27 patients had clinical stage IVA disease. All patients completed the full planned dose of radiation therapy. The most common ≥ grade 3 adverse events were lymphopenia, mucositis (functional), and dysphagia. With a median follow-up of 33.8 months, 2-year PFS was 88.5% (95% confidence interval ...Continue Reading

References

Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J AdelsteinArlene A Forastiere
Dec 3, 2003·The New England Journal of Medicine·Arlene A ForastiereJay Cooper
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Panayiotis A KyzasJohn P A Ioannidis
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Jun 10, 2010·The New England Journal of Medicine·K Kian AngMaura L Gillison
Jan 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David S YooDavid M Brizel
Aug 18, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A ArgirisS Kim
Feb 21, 2014·The New England Journal of Medicine·Krishnansu S TewariBradley J Monk
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Kian AngRita S Axelrod

❮ Previous
Next ❯

Citations

Nov 26, 2015·Advanced Drug Delivery Reviews·Daniel R Wahl, Theodore S Lawrence
Oct 16, 2015·BMC Cancer·James A BonnerEddy S Yang
Nov 9, 2015·Cancer Treatment Reviews·Linda M HenricksJos H Beijnen
Jul 12, 2016·Current Oral Health Reports·Rebecca C Hoesli, Jeffrey S Moyer
May 15, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A ArgirisR L Ferris
Feb 29, 2016·European Journal of Nuclear Medicine and Molecular Imaging·Shih-Hsin ChenTzu-Chen Yen
Jun 2, 2016·Critical Reviews in Oncology/hematology·Kelly K CurtisHelen J Ross
Mar 20, 2018·Cancer Growth and Metastasis·Kimberly M ArnoldJennifer Sims-Mourtada
Apr 14, 2020·Cancers of the Head & Neck·Ida MicailyAthanassios Argiris
Jan 18, 2017·Cancers of the Head & Neck·Paolo Bossi, Francesca Platini
Sep 25, 2019·Surgical Oncology·Lian LiuJunhui Huang
Mar 16, 2021·Frontiers in Oncology·Sandra Ortiz-CuaranPierre Saintigny
Jul 2, 2021·Frontiers in Oncology·Aini HyytiäinenAhmed Al-Samadi
Jun 13, 2021·Head & Neck·Cristiana BergaminiLisa Licitra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.